Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

893

Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal

Riku Tsudome1, Yasunori Suematsu2,3, Kohei Tashiro1

  • 1Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.

Cardiology Research
|January 5, 2026
PubMed
Abstract

Insights

Selective sodium glucose transporter-2 inhibitors (SGLT2i) demonstrate cardio-renal protective effects in heart failure with reduced ejection fraction (HFrEF) patients. Dapagliflozin treatment improved oxidative stress markers, suggesting a link between anti-oxidative and cardio-renal benefits.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Selective sodium glucose transporter-2 inhibitors (SGLT2i) offer cardio-renal protection through osmotic diuresis and natriuresis.
  • Potential pleiotropic effects like anti-oxidative, anti-fibrotic, and anti-senescence actions are suggested but not fully elucidated clinically.

Purpose of the Study:

  • To investigate the effects of SGLT2i, specifically dapagliflozin, in patients with heart failure with reduced ejection fraction (HFrEF).
  • To evaluate changes in pleiotropic serum markers and clinical parameters following dapagliflozin treatment in HFrEF patients.

Main Methods:

  • A cohort of 25 HFrEF patients treated with dapagliflozin was studied.
  • Baseline and 6-month post-treatment data on clinical characteristics, medications, laboratory findings, echocardiography, and serum markers were collected.

Main Results:

  • Dapagliflozin treatment significantly improved serum brain natriuretic peptide, left ventricular ejection fraction, hemoglobin, and urinary N-acetyl-β-D-glycosaminidase.
  • Significant improvements were observed in high-sensitivity C-reactive protein and oxidative stress markers (myeloperoxidase, MMP-1, MMP-9).
  • Anti-fibrosis and anti-senescence markers did not show significant changes.

Conclusions:

  • Dapagliflozin exhibits anti-oxidative effects in HFrEF patients, complementing its known cardio-renal protective actions.
  • These anti-oxidative effects may contribute to the overall cardio-renal benefits of SGLT2i in a clinical context.
Keywords:
Anti-oxidative effectHeart failure with reduced ejection fractionSelective sodium glucose transporter-2 inhibitor

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

834

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559